Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690388 · ClinicalTrials.gov registry record · Phase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
A Phase 3 study of Differentiated Thyroid Cancer, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT03690388: Active Phase 3 study of Differentiated Thyroid Cancer, sponsored by Exelixis.
NCT03690388 is a Phase 3 study of Differentiated Thyroid Cancer that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 187 participants, above the 65-participant average among 5 other Differentiated Thyroid Cancer trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03690388, a Phase 3 study of Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Primary Outcome
Time to the earlier of either radiographic progressive disease (PD) or death from any cause.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
Study Locations (20)
California
- Exelixis Clinical Site #2 - Newport Beach
- Exelixis Clinical Site #98 - Sacramento
- Exelixis Clinical Site #69 - San Francisco
- Exelixis Clinical Site #10 - Stanford
- Exelixis Clinical Site #3 - Torrance
Florida
- Exelixis Clinical Site #94 - Miami
- Exelixis Clinical Site #93 - Orlando
- Exelixis Clinical Site #6 - Tampa
Michigan
- Exelixis Clinical Site #80 - Ann Arbor
- Exelixis Clinical Site #78 - Detroit
- Exelixis Clinical Site #22 - Detroit
Missouri
- Exelixis Clinical Site #63 - Columbia
- Exelixis Clinical Site #42 - St Louis
Colorado
- Exelixis Clinical Site #9 - Aurora
Connecticut
- Exelixis Clinical Site #21 - New Haven
District of Columbia
- Exelixis Clinical Site #4 - Washington D.C.
Illinois
- Exelixis Clinical Site #164 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
What the registry record for NCT03690388 still lists
NCT03690388 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 65-participant average among 5 other Differentiated Thyroid Cancer trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Differentiated Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03690388 names 20 study sites across 11 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03690388 about?
NCT03690388 is a clinical study titled "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy". The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth fac...
What is the current status of trial NCT03690388?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2018-10-05. Estimated completion is 2026-07-31.
What conditions does trial NCT03690388 study?
This clinical trial studies the following conditions: Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT03690388?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03690388?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03690388 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Differentiated Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
COMPLETED · Phase 3
-
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
RECRUITING
-
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
RECRUITING · Phase 2
-
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI